4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background Extracorporeal life support (ECLS) is increasingly used in the treatment of
infarct-related cardiogenic shock despite a lack of evidence regarding its effect on mortality …

Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background Whether acetazolamide, a carbonic anhydrase inhibitor that reduces proximal
tubular sodium reabsorption, can improve the efficiency of loop diuretics, potentially leading …

Background The role of catheter ablation in patients with symptomatic atrial fibrillation and
end-stage heart failure is unknown. Methods We conducted a single-center, open-label trial …

Background Ferric carboxymaltose therapy reduces symptoms and improves quality of life in
patients who have heart failure with a reduced ejection fraction and iron deficiency …